ASCO 2022 IMMUNIB Trial: A Single-Arm, Phase II Study Evaluating Safety & Efficacy of Nivo in Combination With Lenvatinib in Advanced Stage HCC

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ASCO 2022 IMMUNIB Trial: A Single-Arm, Phase II Study Evaluating Safety & Efficacy of Nivo in Combination With Lenvatinib in Advanced Stage HCC

By ASCO 2022 Conference Coverage FEATURING Arndt Vogel

0 views

June 15, 2022

Comments 0

Safety and Efficacy Data of a TKI Monotherapy in HCC

Feat. J. Mizrahi

Explore the mechanism of Action of a TKI in HCC

Feat. W. Keiser

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl